Integrative Analysis Identifies an Older Female-linked AML Patient Group with Better Risk in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Overview

Journal Blood Cancer J

Date 2022 Sep 23

PMID 36151075

Authors

Franck Rapaport

Kenneth Seier

Yaseswini Neelamraju

Duane Hassane

Timour Baslan

Daniel T Gildea

Samuel Haddox

Tak Lee

H Moses Murdock

Caroline Sheridan

Alexis Thurmond

Ling Wang

Martin Carroll

Larry D Cripe

Hugo Fernandez

Christopher E Mason

Elisabeth Paietta

Gail J Roboz

Zhuoxin Sun

Martin S Tallman

Yanming Zhang

Mithat Gonen

Ross Levine

Ari M Melnick

Maria Kleppe

Francine E Garrett-Bakelman

Affiliations

Soon will be listed here.

Citing Articles

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y Int J Hematol. 2023; 119(1):24-38.

PMID: 38015362 DOI: 10.1007/s12185-023-03677-w.

References

Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-65. DOI: 10.1182/blood-2009-11-254441. View

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

Eisfeld A, Kohlschmidt J, Mrozek K, Blachly J, Walker C, Nicolet D . Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018; 32(6):1338-1348. PMC: 5992022. DOI: 10.1038/s41375-018-0068-2. View

Itzykson R, Fournier E, Berthon C, Rollig C, Braun T, Marceau-Renaut A . Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021; 138(7):507-519. DOI: 10.1182/blood.2021011103. View

Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C . Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464. PMC: 5754190. DOI: 10.1056/NEJMoa1614359. View

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

Cripe L, Uno H, Paietta E, Litzow M, Ketterling R, Bennett J . Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010; 116(20):4077-85. PMC: 2993615. DOI: 10.1182/blood-2010-04-277269. View

Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S . Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562(7728):526-531. PMC: 6280667. DOI: 10.1038/s41586-018-0623-z. View

Bowman R, Busque L, Levine R . Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell. 2018; 22(2):157-170. PMC: 5804896. DOI: 10.1016/j.stem.2018.01.011. View

10.

Meyer M, Rubsamen D, Slany R, Illmer T, Stabla K, Roth P . Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One. 2009; 4(11):e7768. PMC: 2767509. DOI: 10.1371/journal.pone.0007768. View

11.

Wiernik P, Sun Z, Cripe L, Rowe J, Fernandez H, Luger S . Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021; 194(2):309-318. PMC: 8532194. DOI: 10.1111/bjh.17523. View

12.

Fernandez H, Sun Z, Yao X, Litzow M, Luger S, Paietta E . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361(13):1249-59. PMC: 4480917. DOI: 10.1056/NEJMoa0904544. View

13.

Vo T, Ryan J, Carrasco R, Neuberg D, Rossi D, Stone R . Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012; 151(2):344-55. PMC: 3534747. DOI: 10.1016/j.cell.2012.08.038. View

14.

Samra B, Konopleva M, Isidori A, Daver N, DiNardo C . Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Front Oncol. 2020; 10:562558. PMC: 7675064. DOI: 10.3389/fonc.2020.562558. View